MingSight Pharmaceuticals, Inc.
Selective protein kinase C (PKC) inhibitors for disease treatment
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Latest Form D
- $10M, Nov 2021
- Total capital
- $10M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $10M
- 1 Form D · last Nov 2021
- 59 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 22 pending · first 2017
- Rank in peer group#269 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$10M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#269 · top 19%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Michael NiesmanResearcherExecutive Officer, DirectorLinked by 3 patents
- Kai ZhangExecutive Officer, DirectorNamed in SEC Form D filings
- Xintao XiaDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 27- PendingPkc Inhibitor Solid State FormsUSPTOApplication 19307962
- GrantedPkc Inhibitor Solid State FormsUSPTOUS 12,415,807
- PendingTreatment Of Autoimmune DiseaseUSPTOApplication 17976710
Show all 27 patent records
- Pkc Inhibitor Solid State FormsDec 25, 2025 · Application 19307962Pending
- Pkc Inhibitor Solid State FormsSep 16, 2025 · US 12,415,807Granted
- Treatment Of Autoimmune DiseaseMar 30, 2023 · Application 17976710Pending
- Compositions Comprising Pkc-beta Inhibitors And Processes For The Preparation ThereofJan 26, 2023 · Application 17782091Pending
- Treatment Of CancerJun 30, 2022 · Application 17472130Pending
- Treatment Of CancerJun 30, 2022 · Application 17472544Pending
- Treatment Of CancerJan 6, 2022 · Application 17469715Pending
- Treatment Of CancerDec 30, 2021 · Application 17469551Pending
- Treatment Of CancerOct 26, 2021 · US 11,154,555Granted
- Pkc Inhibitor Solid State FormsAug 31, 2021 · US 11,104,679Granted
- Combination Therapy For The Treatment Of CancerMar 11, 2021 · Application 16962806Pending
- Treatment Of Autoimmune DiseaseNov 8, 2018 · Application 15774996Pending
- Treatment Of Autoimmune DiseaseMay 29, 2018 · US 9,980,965Granted
- Treatment Of Autoimmune DiseaseNov 14, 2017 · US 9,814,716Granted
- Compositions Comprising Pkc-beta Inhibitors And Processes For The Preparation ThereofApplication PCTUS2022032684Pending
- Pkc Inhibitor Solid State FormsApplication PCTUS2018034740Pending
- Combination Therapy For The Treatment Of CancerApplication 62618555Pending
- Treatment Of CancerApplication PCTUS2017042011Pending
- Pkc Inhibitor Solid State FormsApplication 62511210Pending
- Treatment Of Autoimmune DiseaseApplication PCTUS2016061824Pending
- Treatment Of CancerApplication 62362369Pending
- Treatment Of Autoimmune DiseaseApplication 62258190Pending
- Compositions Comprising Pkc-beta Inhibitors And Processes For The Preparation ThereofApplication PCTUS2020063480Pending
- Treatment Of Autoimmune DiseaseApplication PCTUS2015032315Pending
- Compositions Comprising Pkc-beta Inhibitors And Processes For The Preparation ThereofApplication 62944699Pending
- Compositions Comprising Pkc-beta Inhibitors And Processes For The Preparation ThereofApplication 63208946Pending
- Combination Therapy For The Treatment Of CancerApplication PCTUS2019014015Pending
Related companies, and why
- Phenomune, LLCSimilar federal contract value in Biotech · null in contracts
- Manifold Technologies Ltd.Similar federal contract value in Biotech · null in contracts
- Virax Biolabs Group LtdSimilar federal contract value in Biotech · null in contracts
- Attivare Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Inventprise LLCSimilar federal contract value in Biotech · null in contracts
- YAP Therapeutics IncSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .